Evidence map›Paper›PMID 40918945›Full record

ArticleInternational journal of nanomedicine2025

Cu

Yadong Liu, Huiyan Lv, Yaodong Chen, Shazhou Ye, Zhong Zheng, Lei Chen, Zejun Yan, Xingyi Li

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yadong Liu *Department of Urology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Huiyan Lv *Department of Nephrology, the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
Yaodong Chen *Department of Ultrasonic Imaging, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Shazhou YeDepartment of Urology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Zhong ZhengDepartment of Urology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Lei ChenDepartment of Urology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Zejun YanDepartment of Urology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Xingyi LiDepartment of Ultrasonic Imaging, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Due to the complex structure and variable microenvironment in the progression of bladder cancer, the efficacy of traditional treatment methods such as surgery and chemotherapy is limited. Tumor residual, recurrence and metastasis are still difficult to treat. The integration of diagnosis and treatment based on nanoparticles can offer the potential for precise tumor localization and real-time therapeutic monitoring. Photodynamic therapy (PDT), which generates reactive oxygen species (ROS) under laser irradiation, can be effectively combined with photothermal therapy (PTT) and chemodynamic therapy (CDT) to target non-muscle-invasive bladder tumors. In this study, Cu Methods: The generation of ROS was detected to evaluate the potential of PDT and copper ion-induced CDT. Additionally, the PA imaging capability and biosafety of the nanoparticles were systematically evaluated. Finally, the anti-tumor efficacy of Cu Results: Cu Conclusion: This study systematically explores the combined anti-cancer mechanisms from the perspective of epithelial-mesenchymal transition, providing a theoretical and technical foundation for bladder cancer treatment.

Indexed as

NanoparticlesPhotochemotherapyPhotothermal TherapyUrinary Bladder NeoplasmsAnimalsCell Line, TumorCell SurvivalCombined Modality TherapyCopperHumansMiceMice, Inbred BALB CMice, NudePhotoacoustic TechniquesPhotosensitizing AgentsReactive Oxygen SpeciesCopperPhotosensitizing AgentsReactive Oxygen Speciesbladder cancerchemodynamic therapyCu2(OH)PO4@PAAphotodynamic therapyphotothermal therapy

Identifiers

PMID40918945
PMCPMC12412768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.